Watching ABVC Biopharma, Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsOther EventsItem 8.01 · 8-KMEDIUM RiskNegative
ABVC Biopharma, Inc.
Filed: Aug 3, 2026CIK: 001-40700
AI Executive Summary
AI-powered analysis of 8-K filing content
ABVC Biopharma postponed the distribution of BioKey (Cayman), Inc. ordinary shares originally scheduled for August 3, 2026, to allow time for finalizing administrative, regulatory, and tax-related requirements. The delay impacts shareholders who were expecting to receive 0.169464 BioKey shares per ABVC share held.
Key Takeaways
Distribution of BioKey shares postponed from August 3, 2026 to an unspecified future date
Record date for the distribution remains unchanged; shareholders will still receive 0.169464 BioKey shares per ABVC common share
2 more takeaways
Filing Overview
Form Type8-K
Filing DateAug 3, 2026
Item8.01
CategoryOther Events
CIK001-40700
Accession #0001173313
Risk LevelMEDIUM
SentimentNegative
Signalrisk
Topics
divestitureregulatory
What This Means
Other material events not covered by specific item numbers. The content of the filing determines significance.